Novo Nordisk (NYSE:NVO)<\/a>and US telehealth company Hims & Hers (NYSE:HIMS) have announced a collaboration that will bring the Danish drugmaker\u2019s weight-loss medications Wegovy and Ozempic to Hims & Hers\u2019 platform, ending a recent legal dispute between the two companies.<\/p>\nThe partnership marks a shift in strategy for Hims & Hers, which will now provide US customers access to a broad assortment of FDA-approved GLP-1 treatments, including semaglutide injections and tablets at various dosages.<\/p>\n
The platform will continue to offer compounded semaglutide on a limited basis only when clinically necessary, while ceasing the promotion of compounded GLP-1s in marketing materials.<\/p>\n
\u201cThe US\u00a0weight loss landscape has evolved with more affordable, FDA-approved medications and flexible dosing options,\u201d Hims & Hers co-founder and CEO Andrew Dudum said in a statement.<\/p>\n
\u201cWe see tremendous growth opportunities with the expanding assortment of branded GLP-1 medications and are excited to have a great partner in Novo Nordisk.\u201d<\/p>\n
The agreement includes the introduction of Ozempic (0.5 mg, 1 mg, and 2 mg injections) and Wegovy (1.7 mg and 2.4 mg injections, as well as 1.5 mg, 4 mg, 9 mg, and 25 mg tablets) to the platform later this month.<\/p>\n
Hims & Hers plans to educate customers on the full range of available treatments and support transitions to FDA-approved medications when clinically appropriate.<\/p>\n
As part of the announcement, Novo Nordisk confirmed it is dismissing its lawsuit against Hims & Hers, which had been filed in February over a $49 compounded alternative to Wegovy, without prejudice.<\/p>\n
Shares of Hims & Hers surged almost 38% on the news, while Novo Nordisk shares added 2.7%.<\/p>\n","protected":false},"excerpt":{"rendered":"Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute Proactive uses images sourced…\n","protected":false},"author":2,"featured_media":36670,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[621,1440,7008,272,780],"class_list":{"0":"post-36669","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-hims","9":"tag-hims-hers","10":"tag-legal-dispute","11":"tag-novo-nordisk","12":"tag-weight-loss-medications"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116203696040495012","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/36669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=36669"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/36669\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/36670"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=36669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=36669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=36669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Hims](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/03\/2d16c51c886db5725459cef697c88a71.jpeg\")
Hims & Hers partners with Novo Nordisk to sell Wegovy and Ozempic, ending dispute Proactive uses images sourced from Shutterstock <\/p>\n